Tobias J Weismüller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2267996/publications.pdf

Version: 2024-02-01

201674 118850 3,951 86 27 62 citations g-index h-index papers 103 103 103 5270 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Impact on followâ€up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	3.9	15
2	New-onset autoimmune hepatitis following mRNA COVID-19 vaccination in a 36-year-old woman with primary sclerosing cholangitis – should we be more vigilant?. Journal of Hepatology, 2022, 76, 218-220.	3.7	28
3	Model for end-stage liver disease underestimates mortality of patients with acute-on-chronic liver failure waiting for liver transplantation. Digestive and Liver Disease, 2022, 54, 784-790.	0.9	4
4	Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Scientific Reports, 2022, 12, 1011.	3.3	12
5	Management of esophageal perforations in infants by endoscopic vacuum therapy: a single center case series. BMC Gastroenterology, 2022, 22, .	2.0	7
6	Non-invasive assessment of liver fibrosis in autoimmune hepatitis: Diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction. Abdominal Radiology, 2021, 46, 2458-2466.	2.1	11
7	Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells. Cancer Immunology, Immunotherapy, 2021, 70, 1451-1464.	4.2	23
8	Role of Intraductal RFA: A Novel Tool in the Palliative Care of Perihilar Cholangiocarcinoma. Visceral Medicine, 2021, 37, 39-47.	1.3	7
9	Intensified Endoscopic Evaluation for Biliary Complications After Orthotopic Liver Transplantation. Annals of Transplantation, 2021, 26, e928907.	0.9	4
10	Tumor Infiltrating Neutrophils Are Frequently Found in Adenocarcinomas of the Biliary Tract and Their Precursor Lesions with Possible Impact on Prognosis. Journal of Personalized Medicine, 2021, 11, 233.	2.5	4
11	Primary sclerosing cholangitis with moderately elevated serumâ€lgG4 – characterization and outcome of a distinct variant phenotype. Liver International, 2021, , .	3.9	1
12	Upper Abdominal Pain Following Endoscopic Ultrasound-Guided Pancreatic Biopsy. Deutsches Ärzteblatt International, 2021, 118, 461.	0.9	0
13	Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation. Medicine (United States), 2021, 100, e27082.	1.0	5
14	Disturbed hepatic sulfation capacity: another piece of the puzzle in the complex pathogenetic mechanism of primary sclerosing cholangitis?. Polish Archives of Internal Medicine, 2021, 131, 779-780.	0.4	0
15	A Combined TLR7/TLR9/GATA3 Score Can Predict Prognosis in Biliary Tract Cancer. Diagnostics, 2021, 11, 1597.	2.6	1
16	Double is not always better: rare cause of chronic pain and weight loss in an Asian female patient with an anomaly of the bile duct system. Gastrointestinal Endoscopy, 2021, , .	1.0	0
17	Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation. Clinical Case Reports (discontinued), 2021, 9, e04782.	0.5	2
18	Percutaneous transhepatic cholangiodrainage in patients with PSC: a multicentre, retrospective analysis., 2021, 59, .		1

#	Article	IF	Citations
19	Primäsklerosierende Cholangitis. , 2021, , 377-382.		O
20	TIPS for the management of stomal variceal bleeding due to cirrhotic and non-cirrhotic portal hypertension. Zeitschrift Fur Gastroenterologie, 2021, , .	0.5	0
21	Management of post-operative pancreatic fistulas following Longmire–Traverso pylorus-preserving pancreatoduodenectomy by endoscopic vacuum-assisted closure therapy. BMC Gastroenterology, 2021, 21, 425.	2.0	7
22	First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis. Frontiers in Oncology, 2021, 11, 717397.	2.8	8
23	Dye chromoendoscopy leads to a higher adenoma detection in the duodenum and stomach in patients with familial adenomatous polyposis. Endoscopy International Open, 2020, 08, E1308-E1314.	1.8	5
24	Direct acute respiratory distress syndrome after gastric perforation caused by an intragastric balloon: a case report. BMC Anesthesiology, 2020, 20, 182.	1.8	1
25	Transpapillary tissue sampling of biliary strictures: balloon dilatation prior to forceps biopsy improves sensitivity and accuracy. Scientific Reports, 2020, 10, 17423.	3.3	8
26	Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease. Liver Transplantation, 2020, 26, 1652-1657.	2.4	8
27	Endoscopic resection of a giant gastric fundus adenoma with highâ€grade dysplasia by a multiâ€step endoscopic mucosal resection and submucosal dissection hybrid technique. Digestive Endoscopy, 2020, 32, e47-e48.	2.3	0
28	Genetic variants of UDPâ€glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis. Liver International, 2020, 40, 1645-1654.	3.9	2
29	Editorial: shining a light on cholangiocarcinoma—a new dawn for photodynamic therapy? Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 953-954.	3.7	0
30	Transcutaneous vagal nerve stimulation improves gastroenteric complaints in Parkinson's disease patients. NeuroRehabilitation, 2019, 45, 449-451.	1.3	16
31	Recommendations on the Use of Magnetic Resonance Imaging for Collaborative Multicenter Studies in Primary Sclerosing Cholangitis. Hepatology, 2019, 69, 1358-1359.	7.3	7
32	Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Alimentary Pharmacology and Therapeutics, 2019, 49, 437-447.	3.7	55
33	Percutaneous transgastral biliodigestive diversion as treatment option for benign recurrent intrahepatic cholestasis. Liver International, 2019, 39, 222-222.	3.9	1
34	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	12.1	42
35	Combined photodynamic therapy with systemic chemotherapy improves survival of patients with irresectable cholangiocarcinoma. Journal of Hepatology, 2018, 68, S206.	3.7	0
36	Endoscopic Ultrasound-Guided Drainage and Treatment of Symptomatic Pancreatic Fluid Collection following Acute or Acute-on-Chronic Pancreatitis – A Single Center Case Series. Zentralblatt Fur Chirurgie, 2018, 143, 577-585.	0.3	3

#	Article	IF	CITATIONS
37	Followâ€up magnetic resonance imaging/3Dâ€magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. Alimentary Pharmacology and Therapeutics, 2018, 48, 169-178.	3.7	34
38	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	1.3	355
39	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	21.4	230
40	Risk estimation for biliary tract cancer: Development and validation of a prognostic score. Liver International, 2017, 37, 1852-1860.	3.9	21
41	Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy. PLoS Pathogens, 2017, 13, e1006373.	4.7	85
42	Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients. Endoscopy International Open, 2016, 04, E1305-E1310.	1.8	27
43	Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. Liver Transplantation, 2016, 22, 42-52.	2.4	111
44	No Evidence That Azathioprine Increases Risk ofÂCholangiocarcinoma in Patients With Primary SclerosingÂCholangitis. Clinical Gastroenterology and Hepatology, 2016, 14, 1806-1812.	4.4	15
45	Primäsklerosierende Cholangitis. , 2016, , 101-107.		O
46	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. PLoS ONE, 2015, 10, e0140525.	2.5	8
47	A pocket guide to identify patients at risk for chronic kidney disease after liver transplantation. Transplant International, 2015, 28, 519-528.	1.6	16
48	Gadoxetate disodium in patients with primary sclerosing cholangitis: An analysis of hepatobiliary contrast excretion. Journal of Magnetic Resonance Imaging, 2014, 40, 106-112.	3.4	14
49	Differential Serum Levels of Eosinophilic Eotaxins in Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, and Autoimmune Hepatitis. Journal of Interferon and Cytokine Research, 2014, 34, 204-214.	1.2	49
50	Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 1733-1738.	4.4	66
51	962 HEPATOCELLULAR CARCINOMA DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RISK OF HEPATOBILIARY MALIGNANCY IN CIRRHOTIC PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS. Journal of Hepatology, 2013, 58, S396.	3.7	0
52	Antineutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2013, 48, 1205-1212.	1.5	10
53	Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut, 2013, 62, 122-130.	12.1	131
54	954 PRIMARY SCLEROSING CHOLANGITIS WITH FEATURES OF AUTOIMMUNE HEPATITIS: CHARACTERISTICS AT FIRST PRESENTATION AND LONG TERM OUTCOME IN A LARGE, MULTICENTER COHORT FROM GERMANY. Journal of Hepatology, 2013, 58, S393.	3.7	0

#	Article	IF	CITATIONS
55	97 BILIARY STRICTURES AND RECURRENT DISEASE AFTER LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS – A LARGE, MULTICENTER COHORT ANALYSIS WITH LONG-TERM FOLLOW-UP. Journal of Hepatology, 2013, 58, S42-S43.	3.7	O
56	Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at <i>GPR35</i> and <i>TCF4</i> . Hepatology, 2013, 58, 1074-1083.	7.3	150
57	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	21.4	339
58	Screening colonoscopy in liver transplant candidates: risks and findings. Clinical Transplantation, 2013, 27, E161-8.	1.6	13
59	Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy. Endoscopy, 2012, 44, 48-52.	1.8	40
60	Prospective Analysis of Upper and Lower Gastrointestinal Screening Endoscopy as Part of the Candidate Evaluation before Liver Transplantation. Transplantation, 2012, 94, 225.	1.0	0
61	112 URINE PROTEOMIC ANALYSIS DIFFERENTIATES CHOLANGIOCARCINOMA FROM PRIMARY SCLEROSING CHOLANGITIS AND OTHER BENIGN BILIARY DISEASES. Journal of Hepatology, 2012, 56, S49-S50.	3.7	O
62	Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. Journal of Hepatology, 2012, 57, 366-375.	3.7	196
63	Renal Comorbidity After Solid Organ and Stem Cell Transplantation. American Journal of Transplantation, 2012, 12, 1691-1699.	4.7	25
64	Gastrointestinal: PEG feeding tube migration into the colon; a late manifestation. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1254-1254.	2.8	8
65	Value of the preoperative SOFT-score, P-SOFT-score, SALT-score and labMELD-score for the prediction of short-term patient and graft survival of high-risk liver transplant recipients with a pre-transplant labMELD-score ≥30. Annals of Transplantation, 2012, 17, 11-17.	0.9	14
66	Three Genetic Susceptibility Loci Indicate a Role for IL2, REL and CARD9 in Primary Sclerosing Cholangitis. Gastroenterology, 2011, 140, S-906.	1.3	0
67	Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology, 2011, 46, 1092-1098.	1.5	94
68	Medical and endoscopic therapy of primary sclerosing cholangitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 741-752.	2.4	18
69	Asparagus and jejunal-through-PEG: An unhappy encounter in intrajejunal levodopa infusion therapy. Parkinsonism and Related Disorders, 2011, 17, 67-69.	2.2	14
70	Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany - limitations of the â€~sickest first'-concept. Transplant International, 2011, 24, 91-99.	1.6	134
71	Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nature Genetics, 2011, 43, 17-19.	21.4	221
72	Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology, 2011, 53, 875-884.	7.3	143

#	Article	lF	CITATIONS
73	Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for <i>IL2, REL</i> , and <i>CARD9</i> . Hepatology, 2011, 53, 1977-1985.	7.3	110
74	Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival. Hepatology, 2011, 54, 2114-2124.	7.3	42
75	Peripapillary Duodenal Varices as a Rare Cause of Severe Bleeding in a Patient with No Other Signs of Portal Hypertension – Successful Endoscopic Treatment with Cyanoacrylate Injection. Zeitschrift Fur Gastroenterologie, 2011, 49, 591-595.	0.5	2
76	Ferritin and liver allocation? Impact on mortality not only on the waiting list but also after orthotopic liver transplantation should be considered. Hepatology, 2010, 52, 392-393.	7.3	5
77	Reply: Ferritin and Liver Allocation? Impact on Mortality Not Only on the Waiting List But Also After Orthotopic Liver Transplantation Should Be Considered. Hepatology, 2010, 52, 393-393.	7.3	O
78	Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis. PLoS ONE, 2010, 5, e12403.	2.5	106
79	Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointestinal Endoscopy, 2010, 72, 284-291.	1.0	102
80	Genome-Wide Association Analysis in Primary Sclerosing Cholangitis. Gastroenterology, 2010, 138, 1102-1111.	1.3	325
81	The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transplant International, 2009, 22, 970-978.	1.6	76
82	The challenges in primary sclerosing cholangitis $\hat{a} \in \text{``Aetiopathogenesis'}$, autoimmunity, management and malignancy. Journal of Hepatology, 2008, 48, S38-S57.	3.7	138
83	Recurrence of primary sclerosing cholangitis after liver transplantation – A model for pathogenesis?. Journal of Hepatology, 2008, 49, 864-865.	3.7	O
84	Prediction of survival after liver transplantation by pre-transplant parameters. Scandinavian Journal of Gastroenterology, 2008, 43, 736-746.	1.5	70
85	Upregulation of Phospholipase D Expression and Activation in Ventricular Pressure-Overload Hypertrophy. Journal of Pharmacological Sciences, 2005, 98, 244-254.	2.5	17
86	Effects of Norepinephrine and Cardiotrophin-1 on Phospholipase D Activity and Incorporation of Myristic Acid Into Phosphatidylcholine in Rat Heart. Journal of Pharmacological Sciences, 2004, 95, 335-340.	2.5	4